Can I Take Folate with Avodart (Dutasteride)?

The Short Answer: No Known Interaction

Folate does not interact with dutasteride at any recognized pharmacological checkpoint. The two compounds travel entirely separate metabolic roads. Dutasteride is processed by hepatic cytochrome P450 enzymes CYP3A4 and CYP3A5, while folate is absorbed through the proton-coupled folate transporter (PCFT) in the jejunum and metabolized through one-carbon folate cycle enzymes including MTHFR, MTHFS, and SHMT [1, 2]. Neither pathway influences the other.

Why Interaction Databases Show No Flag

Major drug-interaction screening tools, including the Natural Medicines Comprehensive Database and the FDA's drug interaction guidance framework, classify interactions by pharmacokinetic (absorption, distribution, metabolism, excretion) and pharmacodynamic (additive or opposing biological effects) mechanisms [3]. Folate satisfies neither criterion relative to dutasteride. It does not bind CYP3A4, does not alter plasma protein binding of dutasteride, and produces no overlapping or opposing endocrine effect on androgen metabolism [2, 4].

What Dutasteride Actually Does

Dutasteride inhibits both type 1 and type 2 isoforms of 5-alpha reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT). In the ARIA trial (N=917), dutasteride 0.5 mg daily reduced serum DHT by approximately 90% within two weeks [5]. Folate has no known effect on 5-alpha reductase activity, androgen receptor signaling, or DHT synthesis.

What Folate Actually Does

Folate (vitamin B9) is a water-soluble B vitamin required for DNA synthesis, DNA methylation, and amino acid metabolism. The biologically active form, 5-methyltetrahydrofolate (5-MTHF), donates methyl groups in the methionine cycle [6]. Deficiency raises homocysteine, a marker associated with cardiovascular and cognitive risk [7]. None of these pathways converge with the androgen axis targeted by dutasteride.

MTHFR Variants and Why They Matter for Dutasteride Users

Men taking dutasteride for BPH or androgenetic alopecia are often middle-aged or older, a demographic with higher rates of undetected MTHFR polymorphisms and borderline folate status. The MTHFR C677T variant reduces enzyme activity by approximately 70% in homozygous TT carriers, impairing conversion of folic acid to bioactive 5-MTHF [8].

Prevalence and Clinical Impact

The homozygous TT genotype of MTHFR C677T occurs in roughly 10-15% of individuals of European descent and up to 25% of some Mediterranean and Hispanic populations [8]. A 2022 meta-analysis in the Journal of Clinical Medicine (N=28,364) confirmed that TT carriers have significantly elevated fasting homocysteine compared with CC genotype controls (mean difference 3.1 µmol/L, 95% CI 2.7-3.5, P<0.001) [9]. Elevated homocysteine above 15 µmol/L is associated with a roughly 1.7-fold increase in cardiovascular event risk per a Cochrane review of folate supplementation trials [7].

Choosing the Right Folate Form

For men with confirmed MTHFR C677T TT genotype, supplementing with pre-methylated 5-methyltetrahydrofolate (L-methylfolate or Metafolin) at 400 mcg to 1,000 mcg daily bypasses the enzymatic step that is impaired [6]. Folic acid (the synthetic oxidized form) requires reduction by dihydrofolate reductase (DHFR) and then methylation by MTHFR before it becomes active; this multi-step conversion is rate-limited in TT carriers [8]. A 2017 randomized controlled trial in Nutrients (N=149) found L-methylfolate supplementation reduced plasma homocysteine by 2.2 µmol/L more than equivalent-dose folic acid in MTHFR TT participants over 12 weeks [10]. Dutasteride therapy does not change this recommendation in either direction.

When to Test MTHFR Status

Not every dutasteride user needs MTHFR testing. Testing is reasonable when a patient has unexplained hyperhomocysteinemia, a personal or family history of premature cardiovascular disease, recurrent pregnancy loss in a female partner, or a prior neural tube defect pregnancy [8]. Serum homocysteine testing (CPT 83090) is the more clinically actionable first step in most primary care settings, since homocysteine reflects functional folate status regardless of genotype [7].

Pharmacokinetics: Why Folate Cannot Alter Dutasteride Levels

Understanding the absorption and metabolism of each compound shows clearly why no dose separation or timing restriction is needed.

Dutasteride Pharmacokinetics

Dutasteride 0.5 mg reaches peak plasma concentration (Tmax) at approximately 2-3 hours after oral dosing. Bioavailability is about 60%, and the drug is more than 99% protein-bound in plasma. Hepatic metabolism via CYP3A4 and CYP3A5 produces three active metabolites: 4-hydroxydutasteride, 1,2-dihydrodutasteride, and 6-hydroxydutasteride [4]. The terminal half-life is roughly 5 weeks, which is why serum PSA suppression persists for months after discontinuation. The FDA-approved prescribing information for dutasteride (NDA 021319) lists CYP3A4 inhibitors such as ketoconazole and ritonavir as clinically relevant interaction risks, not B vitamins [4].

Folate Pharmacokinetics

Dietary folates and supplemental folic acid are absorbed primarily in the proximal jejunum via PCFT (SLC46A1) and, at higher concentrations, the reduced folate carrier (RFC/SLC19A1) [1]. First-pass hepatic conversion to 5-MTHF occurs before systemic circulation. Renal clearance removes excess folate; there is no enterohepatic recirculation that could concentrate folate in a way that might affect CYP enzymes. In vitro studies of folate at physiological and supra-physiological concentrations have not demonstrated inhibition of CYP3A4, CYP3A5, CYP2D6, or other major drug-metabolizing isoforms [2].

Protein-Binding Displacement

Dutasteride's extremely high plasma protein binding (>99%) raises a theoretical question about displacement by co-administered agents. Folate circulates largely as 5-MTHF loosely associated with albumin and binds to the high-affinity folate receptor (FR-alpha) on cell surfaces [1]. There is no competitive binding at the sites dutasteride occupies on albumin or sex hormone-binding globulin, so displacement-based interactions are not a plausible mechanism [2, 4].

Folate and Prostate Health: What the Research Shows

A reasonable secondary question is whether folate supplementation itself affects prostate biology in men on dutasteride for BPH or hair loss.

Folate and Prostate Cancer Risk: A Nuanced Picture

The relationship between folate and prostate health is more complex than a simple beneficial or harmful label. The SELECT trial ancillary analysis (N=35,533) found no statistically significant association between serum folate quartiles and prostate cancer incidence (HR 0.98, 95% CI 0.87-1.10) [11]. A 2019 meta-analysis in the European Journal of Nutrition (N=579,365 men across 10 cohort studies) found no significant association between total folate intake and prostate cancer risk (RR 0.97, 95% CI 0.91-1.04) [12].

High-Dose Folic Acid and the CAPS Trial

One signal worth knowing: the CAPS randomized trial (N=643) tested 1 mg folic acid daily versus placebo in men with a history of colorectal adenoma. Over 10 years, folic acid supplementation was associated with a higher risk of prostate cancer (RR 1.93, 95% CI 1.10-3.40, P=0.025) [13]. This finding has not been replicated in population-based cohort studies, and the dose in CAPS (1,000 mcg/day as folic acid, not 5-MTHF) was specific to a high-adenoma-risk population. Standard supplementation doses of 400-800 mcg daily in otherwise healthy men have not shown this signal [12]. Men with a personal history of colorectal adenoma should discuss any folic acid dose above 400 mcg with their physician before starting.

Dutasteride's Effect on PSA and Cancer Screening

Dutasteride suppresses PSA by approximately 50% after 6 months of continuous use [4, 5]. Clinicians monitoring prostate health in these patients should double the observed PSA value to estimate the pre-treatment equivalent, per the AUA BPH Guidelines [14]. Folate supplementation does not alter PSA levels and therefore does not complicate this monitoring calculation.

Drug Interactions That Dutasteride Users Should Actually Watch For

Folate is not on this list. Compounds that do carry clinically meaningful interaction risk with dutasteride include CYP3A4 inhibitors, which can raise dutasteride plasma concentrations.

CYP3A4 Inhibitors

Ketoconazole, itraconazole, ritonavir, clarithromycin, and diltiazem inhibit CYP3A4 and slow dutasteride clearance [4]. Co-administration with ritonavir 400 mg twice daily increased dutasteride AUC by approximately 3-fold in pharmacokinetic studies cited in the FDA label. These interactions warrant physician review before concurrent use.

Saw Palmetto and Other 5-ARI Supplements

Saw palmetto (Serenoa repens) also inhibits 5-alpha reductase to a modest degree. While not a pharmacokinetic interaction, additive pharmacodynamic DHT suppression is possible. The CAMUS trial (N=369) found saw palmetto extract had no significant effect on IPSS scores vs. Placebo [15], suggesting limited clinical relevance, but the combination with dutasteride has not been formally studied.

Anticonvulsants and Folate Depletion

This combination is relevant to dutasteride users who also take antiepileptic drugs. Phenytoin, carbamazepine, valproate, and phenobarbital are known folate antagonists. A 2021 review in Epilepsia (N=4,102 patients across 14 studies) confirmed that long-term anticonvulsant therapy is associated with a statistically significant reduction in serum folate levels (mean reduction 3.8 nmol/L, P<0.001) [16]. In this scenario, folate supplementation is clinically indicated regardless of dutasteride use, and the two drugs remain non-interacting.

Practical Dosing and Timing Guidance

No dose adjustment of either agent is required when taking folate and dutasteride together. No timing separation window has been established or recommended, because the mechanisms are entirely independent [2, 4].

Standard Folate Supplementation Ranges

• General population, no MTHFR variant confirmed: 400-800 mcg folic acid or L-methylfolate daily
• MTHFR C677T heterozygous CT genotype: 800-1,000 mcg L-methylfolate daily is a common clinical approach
• MTHFR C677T homozygous TT genotype: 1,000 mcg L-methylfolate daily; some clinicians prescribe up to 5 mg for frank hyperhomocysteinemia
• Concurrent anticonvulsant therapy: 1-5 mg folic acid or L-methylfolate daily under physician supervision [16]

The Tolerable Upper Intake Level (UL) for folic acid set by the National Institutes of Health is 1,000 mcg daily for adults, specifically to avoid masking vitamin B12 deficiency [17]. L-methylfolate does not carry the same B12-masking concern, since it does not correct the macrocytic anemia of B12 deficiency without correcting the neurological damage [6].

Dutasteride Dosing Is Not Affected

Dutasteride 0.5 mg once daily remains the standard approved dose for BPH and the most commonly used off-label dose for androgenetic alopecia. No titration is needed based on folate supplementation status [4, 5].

A Clinical Decision Framework for Dutasteride Users Starting Folate

Step 1. Confirm the reason for folate supplementation (dietary gap, MTHFR variant, anticonvulsant co-therapy, or general wellness).

Step 2. Choose folic acid for patients with no known MTHFR variant and no anticonvulsant co-therapy; choose L-methylfolate for confirmed TT genotype or when absorption of synthetic folic acid is uncertain.

Step 3. Obtain baseline serum homocysteine if the patient has cardiovascular risk factors or is older than 50, since dutasteride users in this demographic frequently overlap with the population at risk for subclinical folate insufficiency.

Step 4. Recheck homocysteine at 3 months if baseline was elevated. Target: below 10-12 µmol/L per ESC cardiovascular prevention guidelines.

Step 5. No PSA adjustment is needed for folate; continue doubling the observed PSA to correct for dutasteride suppression.

Monitoring Recommendations

Routine lab monitoring for a folate-dutasteride combination is not specifically required by any current guideline. Monitoring decisions are driven by individual clinical factors.

Labs Worth Considering at Baseline

Serum folate (reference range typically 4.5-30 nmol/L) and plasma homocysteine (reference <12 µmol/L) are reasonable baseline tests for dutasteride users who are 50 or older, have cardiovascular risk factors, or are starting high-dose supplementation above 1 mg daily [7, 17]. Serum B12 should accompany folate testing to rule out masked B12 deficiency before starting folic acid supplementation, per NIH Office of Dietary Supplements guidance [17].

PSA Monitoring Remains Standard

The AUA 2023 BPH Clinical Guidelines recommend confirming PSA at 3-6 months after starting dutasteride to establish a new baseline, then annual monitoring [14]. The multiplier for dutasteride is approximately 2x the suppressed value. Folate does not interfere with PSA immunoassays [4, 14].

Special Populations

Men Using Dutasteride for Androgenetic Alopecia

Off-label dutasteride 0.5 mg daily for male pattern hair loss is supported by multiple randomized trials, including a 2019 meta-analysis in JAMA Dermatology (7 RCTs, N=1,235) showing a statistically significant advantage in hair density over finasteride at 24 weeks [18]. Men in this cohort are typically younger (25-45 years) and have lower baseline cardiovascular risk, so homocysteine testing is not routinely needed unless symptoms suggest deficiency.

Men With BPH on Multiple Medications

BPH patients are often on alpha-blockers (tamsulosin, alfuzosin), which carry their own drug-interaction profiles. Neither tamsulosin nor alfuzosin interacts with folate [4]. The triple combination of dutasteride, tamsulosin, and folate is pharmacologically benign from an interaction standpoint.

Transgender Women on Gender-Affirming Hormone Therapy

Dutasteride is used off-label in some gender-affirming protocols to reduce androgenic effects. Folate is universally recommended at 400-800 mcg daily in individuals who could become pregnant per ACOG guidelines [19]. No interaction concern arises in this context either.